Multitumor Case Series of Germline <i>BRCA1</i>, <i>BRCA2</i> and <i>CHEK2</i>-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors

In recent years, immune checkpoint inhibitors (ICPI) have become widely used for multiple solid malignancies. Reliable predictive biomarkers for selection of patients who would benefit most are lacking. Several tumor types with somatic or germline alterations in genes involved in the DNA damage resp...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Lisa Kinget, Oliver Bechter, Kevin Punie, Philip R. Debruyne, Hilde Brems, Paul Clement, Eduard Roussel, Yannick Van Herck, Maarten Albersen, Marcella Baldewijns, Patrick Schöffski, Benoit Beuselinck
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2021-08-01
coleção:	Current Oncology
Assuntos:	DNA damage response immune checkpoint inhibitors <i>BRCA1</i> <i>BRCA2</i> <i>CHEK2</i>
Acesso em linha:	https://www.mdpi.com/1718-7729/28/5/280
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!